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  Autoantibodies  against  thyroxin  (T4AA)  and  triiodo-
thyronine  (T3AA)  are  present  in  dogs  with  autoimmune 
thyroiditis  and  have  been  reported  to  interfere  with 
immunoassays. The objectives of this study were to determine 
the frequency of autoantibodies and to determine whether 
interference occurs by T4AA, using a non-immunological 
method (high performance liquid chromatography, HPLC) 
for thyroxin (T4) measurement. Based on clinical symptoms, 
T4 and thyroid stimulating hormone (TSH) concentration, 
1,339 dogs were divided into six groups: Group 1: hypothyroid 
(n = 149); Group 2: subclinical thyroiditis (n = 110); Group 
3: suspicious for non thyroidal illness (n = 691); Group 4: 
biochemical euthyroid (n = 138); Group 5: hypothyroid dogs 
under substitution therapy (n = 141); Group 6: healthy dogs 
(n = 110). The incidence of T4AA and T3AA, determined 
using radiometric assay, was low (0.5% and 3.8%) and higher 
in  hypothyroid  dogs  compared  to  dogs  suspicious  for 
hypothyroidism (Group 2-4) (p＜0.05). T4AA was not detected 
in dogs with normal T4 and elevated TSH. T4 concentrations 
of T4AA positive samples determined using HPLC were 
comparable  to  results  obtained  by  chemiluminescence 
immunoassay. These findings indicate that the probability of 
interference  of  T4AA  leading  to  falsely  elevated  T4 
concentration in the T4 assay seems to be low.
Keywords: autoantibody, autoimmune thyroiditis, canine, 
hypothyroidism, lymphocytic thyroiditis
Introduction 
Autoimmune thyroiditis (AIT) is a frequent cause of primary 
hypothyroidism, which is one of the most common 
endocrinopathies in dogs. Autoantibodies against thyroglobulin 
(TgAA), thyroid hormones (THAA) and thyroid peroxidase 
have been detected in the circulation of dogs with 
hypothyroidism caused by AIT [11,19]. However thyroxin 
(T4) and triiodothyronine (T3) are small molecules with a 
molecular weight of ＜1,000 Dalton and therefore do not 
stimulate an immune response by themselves unless they are 
covalently linked to an immunogen like thyroglobulin. Thus, 
TgAA cross react with T4 and/or T3 as these molecules are 
covalently bound to thyroglobulin [17,21]. It has been reported 
that autoantibodies against triiodothyronine (T3AA) and 
thyroxin (T4AA) in serum samples of dogs with AIT may 
interfere with the immunological assay methods used to 
measure thyroid hormone concentration, leading to falsely 
elevated or reduced concentrations, depending on the assay 
method [14,18]. The measurement of TgAA is considered 
useful as they are associated with AIT and THAA is 
recommended in cases of doubtful T4 results [8]. In dogs, 
falsely elevated T4 concentrations in the presence of T4AA 
have been reported for a commercially available T4 
radioimmunoassay (RIA) [14]. Thus, T4 could falsely lie in 
the normal reference range in a hypothyroid dog with T4AA, 
and a T4 concentration within the normal reference range 
is normally considered to rule out hypothyroidism [13].
Although the reported prevalence of T4AA in dogs with 
clinical signs of hypothyroidism is low (between 0.6% and 
4.0%), the interference of autoantibodies with hormone 
measure is a subject of much debate, especially for cases in 
which the hormone measurements do not fit the clinical sign 
[1,5,14,16,20,22]. Nachreiner et al. [14] described that in 17 
of 1,000 hypothyroid dogs, T4AA caused a falsely elevated 
T4 concentration as measured by RIA, but nothing was known 
about the actual hormone concentration in these dogs. 
Moreover, THAA also appears in dogs with subclinical 
stages of AIT in which T4 concentrations often remain within 
the reference range [11]. Therefore, the first objective of this 
study was to determine the prevalence in Germany of THAA 
in dogs with clinical signs of hypothyroidism, normal T4 and 
elevated thyroid stimulating hormone (TSH) concentrations. 192    Marion Piechotta et al.
Autoantibodies were also determined in hypothyroid dogs 
substituted with levothyroxine (predominantly Forthyron, 
Albrecht, Germany) and clinically healthy dogs. Second, a non- 
immunologic method (high performance liquid chromatography, 
HPLC) for the measurement of T4 in T4AA positive serum 
samples was established to determine the possible interference 
of T4AA in an immunological based T4 assay.
Materials and Methods
Serum samples
A total of 1,339 serum samples from dogs of various breeds, 
ages and both sexes was received from practitioners 
throughout Germany and allocated into six groups. Samples 
were kept frozen at 򰠏20
oC until assay for T4AA, T3AA, T4 
and TSH. Laboratory measurements were done in the 
endocrinology laboratory of the University of Veterinary 
Medicine in Hannover, Germany. Dogs (n = 1,088) with at 
least three clinical symptoms of hypothyroidism (lethargy, 
weight gain, poor hair coat, pyoderma, weakness, bradycardia, 
diarrhea, constipation, anaemia, hyperlipidemia) were allocated 
into four groups on the basis of serum T4 and TSH concentration. 
The laboratory reference range for T4 was 1.7∼4.5 μg/dL 
(21.7∼57.9 nmol/L), while concentrations between 1.1∼
1.6 μg/dL (14.2∼20.6 nmol/L) were designated borderline. 
TSH concentrations ＜0.5 ng/mL were considered physiological. 
The dogs of Group 1 (n = 149, age = 7.5 ± 5.6) were defined 
as hypothyroid (T4＜1.1 μg/dL, TSH＞0.5 ng/dL); those of 
Group 2 (n = 110, age = 7.2 ± 3.4) were classified as 
suspicious for hypothyroidism, subclinical thyroiditis or 
T4AA interference (T4＞1.1 μg/dL, TSH＞0.5 ng/dL); 
those of Group 3 (n = 691, age = 6.9 ± 3.2) were classified 
as non-thyroidal illness or hypothyroidism without elevated 
TSH (T4＜1.7 μg/dL, TSH＜0.5 ng/dL). Dogs with normal 
T4 and TSH concentrations were classified as biochemical 
euthyroid (Group 4; n = 138, age = 5.8 ± 2.9). Hypothyroid 
dogs (n = 141, age = 8.0 ± 2.9) under substitution therapy 
with levothyroxine were assigned to Group 5. The duration 
of the substitution therapy ranged between 3 months and 4.5 
years. In T3AA positive dogs a follow up measurement over 
9 months was possible. Clinically healthy dogs of various 
breeds (Beagle 26%; Terriers 10%, Boxer 7%, Dachshund 
7%, German Shepherd 8%, English Bulldog 5%, Large Swiss 
mountain dog 4%, Labrador Retriever 3%, Border collie 2% 
and other 43%; n = 110, age = 5.1 ± 2.2) from breeding programs 
were allocated into Group 6. T4AA negative serum samples 
for HPLC measurement (n = 5) from clinically healthy dogs 
were made available from another project. T4AA positive 
serum samples for HPLC analysis (n = 6, sufficient volumes 
for repeated analyses) were donated by Prof. Dr. R. 
Nachreiner, Michigan State University, USA.
Autoantibody-determination
Autoantibodies were determined using a radiometric assay 
based on the binding of radiolabelled T4 or T3 to serum 
samples and separating of the bound and free fractions by 
charcoal treatment [14]. Serum samples (100 μL) were 
incubated with 0.02 μCi of 
125I-T4 ([
125I] - Thyroxin, specific 
activity 5,700 μCi/μg; Perkin Elmer, USA) or with 0.02 μCi 
of 
125I-T3 ([
125I]-Triiodothyronine, specific activity 3,300 
μCi/μg; Perkin Elmer, USA) in 500 μL of phosphate buffered 
saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4) containing 5 mM of 8 - anilino - 1 naphtalene 
sulfonic acid for 1 h at 37
oC and for 1 h at 4
oC. Charcoal 
suspension (500 μL; equates to 15 mg activated charcoal per 
tube; Sigma Aldrich, USA) was added. The mixture was 
incubated for 10 min at 4
oC and then centrifuged for 10 min 
at 2,000 × g and 4
oC. The supernatant was decanted and the 
radioactivity in the remaining pellet was counted in a gamma 
counter (LKB-Wallac Clini-Gamma 1272; LKB-Wallac, 
Finland). The percentage of binding was calculated using 
the formula [(T򰠏P)/T] × 100, with T = total activity incubated 
and P = activity in the pellet. Based on a study of Nachreiner 
et al. [14] a threshold of 10% - binding for T3AA and 20% 
- binding for T4AA was chosen to discriminate between 
positive and negative test results. For validation, pooled 
serum from T4AA and T3AA positive dogs, respectively, 
were used as positive controls. Serum from clinically healthy 
dogs with thyroid hormone concentrations within the reference 
range was pooled and used as autoantibody-negative control. 
The accuracy of the radiometric autoantibody-assay was 
tested by repeated analysis of positive and negative controls. 
The intra-assay coefficient of variation (CV%) was 0.8% for 
T3AA-positive controls and 3.3% for T4AA-positive controls. 
The inter-assay CV% was 7.1% for the T3AA-positive 
sample and 9.6% for the T4AA-positive sample. The 
negative control serum was at all times negative for T3AA 
(＜10% - binding) and for T4AA (＜20% - binding).
T4 and TSH immunoassay
T4 and TSH were determined using a commercially available 
chemiluminescence immunoassay (CIA, Immulite canine T4, 
LKCT5 and LKKT5; Siemens Medical Solutions, USA). 
The measurement was performed according to the manufacturer’s 
instructions. The intra-assay CV% for the T4 assay varied 
between 3.9% and 10.8%, while the inter-assay CV% was 
between 5.2% and 13.8%. For TSH measurement, the intra- 
assay CV% ranged between 3.8 and 5.0% and the inter-assay 
CV% ranged between 6.3 and 8.2%. The analytical 
sensitivity for T4 was 0.12 μg/dL (1.5 nmol/L) and for TSH 
0.01 ng/mL.
HPLC
A HPLC method has been developed for the determination 
of T4 in canine serum that includes hormone extraction after 
protein precipitation, purification of the extract by solid 
phase extraction reversed phase HPLC and quantification 
with a UV-monitor [10]. Protein was precipitated by adding Autoantibodies against thyroid hormones in dogs    193
Table 1. Distribution of autoantibodies against thyroxin (T4AA) and triiodothyronine (T3AA)
Group 1 2 3 4
∑Group
1∼4
56
Hypothyroid
Subclinical 
thyroiditis
Non thyroidal 
illness
Euthyroid Substituted Healthy
n = 149 n =110 n = 691 n = 138 n = 1,088 n = 141 n = 110
T4AA
T3AA
4 (2.7%)
a
14 (9.4%)
a
0
a,b
3 (2.7%)
a,b
1 (0.1%)
b
18 (2.6%)
b
0
a,b
6 (4.4%)
a,b
5 (0.5%)
b
41 (3.8%)
b
0
a,b
8 (5.7%)
a
0
a,b
0
b
a,bValues with different superscript letters within each row were significantly different (p＜0.05). 
Table 2. Characteristics of T4AA positive dogs of Group 1 and 3
Breed Sex
Age
(years)
T4 
(µg/dL)
TSH 
(µg/dL)
T4AA 
(%-binding)
T3AA 
(%-binding)
Golden retriever
Poodle pointer
Briard
Samoyed
Cairn terrier
M
M
M
F
M
3
9
7
3
8
0.05
0.29
0.17
0.05
1.3
1.5
6.4
1.5
1.8
0.09
positive (35)
positive (24)
positive (21)
positive (22)
positive (21)
positive (81)
positive (75)
positive (11)
-
positive (11)
T4: thyroxin, TSH : thyroid stimulating hormone.
50% trifluoro acetic acid (0.5 mL, 4
oC) to serum samples (0.5 
mL) and centrifuging the mixture at 4
oC and 2,000 × g for 
20 min. The supernatant was then extracted with 1 mL of 
ethyl acetate. The organic phase was concentrated to 20% 
of its original volume, adjusted to pH 2 with 0.02 M HCl and 
loaded onto a SPE cartridge containing 3 mL Strata TM-X-C 
(Phenomenex, USA). The T4 containing fraction was eluted 
with dichloromethane / 2 - propanol / methanol / 25% 
ammonia (30 : 30 : 30 : 5). After evaporation of the solvent 
the sample was redissolved in 100 μL of 90% methanol, 20 
μL of which were injected into the HPLC system (UV / Vis 
Detector SPD - 20A and a Phenomenex Jupiter 4 μ Proteo 
90 Å column 150 × 2 mm; Shimadzu, Japan). The extract 
was eluted at a flow rate of 0.22 mL/min using a linear solvent 
gradient starting with water/acetonitril 88 : 12 containing 
0.025% TFA proceeding to water/acetonitril 20 : 80 
containing 0.02% TFA after 50 min. For each run, 20 μL of 
reconstituted sample was injected. With UV absorbance 
detection at 228 nm and 215 nm simultaneously, T4 peaks 
of the same height were observed at both wavelengths after 
42 min retention time. Data were evaluated using the 
Shimadzu LC solution software (Shimadzu, Japan). The 
system was calibrated using freshly prepared thyroxin 
standards at concentrations of 0.8, 1.0 and 1.3 μg/dL. The 
T4 concentration was determined in 11 autoantibody 
negative serum samples. The intra-assay CV% was 6.0%. 
The analytical sensitivity in serum samples after protein 
precipitation and extraction of the HPLC method was 0.5 
μg/dL. The recovery was 92% if 1.0 μg/dL thyroxin was 
added to respective serum samples. The correlation between 
T4 results of HPLC and CIA in autoantibody negative serum 
samples was high (r² = 0.91).
Statistical analyses
Descriptive statistics and chi-square analyses were 
calculated with the statistics software Sigma Stat (Version 
11.0; Systat, USA). A value of p＜0.05 was considered to 
be significant.
Results
Autoantibodies against T4 and T3
Of the 1,088 serum samples of dogs with clinical symptoms 
suspicious of hypothyroidism, 13.7% were allocated on the 
basis of their T4 and TSH concentrations to Group 1, 10.1% 
to Group 2, 63.5% to Group 3 and 12.7% to Group 4. The 
distribution of T3AA and T4AA positive dogs in the six 
groups is summarized in Table 1. All of three T3AA positive 
dogs in Group 2 had T4 concentrations between 1.1∼1.7 
μg/dL and elevated TSH but none of the dogs with T4 within 
the reference range (＞1.7 μg/dL) had autoantibodies. THAA 
were found in this study in 20 male (3.8% of all males) and 
21 female (3.2% of all females) dogs, hence no significant 
difference between male and female dogs was found in the 
frequency of autoantibodies (p = 0.949). Four of the 20 male 
dogs were castrated and four of the 21 female dogs were 194    Marion Piechotta et al.
Table 3. Comparison of T4 concentration obtained by high 
performance liquid chromatography (HPLC) and chemiluminescence
immunoassay (CIA) in T4AA negative and positive canine serum
samples
Sample
ID
T4 (µg/dL)
CIA
T4 (µg/dL)
HPLC
T4AA
(% binding)
T4AA
 negative
serum
sample
6
7
8
9
10
2.0
2.0
1.3
2.9
2.2
1.8
2.1
1.3
3.1
2.2
9
11
4
7
2
T4AA
positive
serum
sample
11
12
13
14
15
16
2.1
1.7
0.05
0.13
0.05
0.47
1.8
1.7
ND
ND
ND
ND
63
45
21
38
30
53
ND = no detectable peak, T4≤0.5 μg/dL.
spayed; this difference was not significant. T4AA were only 
detected in four dogs of Group 1 and additionally in one dog 
of Group 3 (Table 2). Four of these five dogs had low T4 
concentrations as measured by CIA. In one dog (Cairn 
terrier) the results for autoantibodies (T4AA and T3AA) and 
T4 concentrations were borderline.
The occurrence of T3AA and T4AA was comparable 
between dogs already substituted with thyroxin and dogs in 
which hypothyroidism was suspected (Group 1∼4). In one 
dog of Group 5, the follow-up measurements of T3AA over 
several months revealed that the T3AA concentration gradually 
decreased to 37% binding after 1 month, to 26% after 5 
months and finally to 19% binding 9 months after beginning 
the substitution therapy. Neither T3AA nor T4AA were 
detected in any clinically healthy dog (Group 6).
Thyroxin determination with HPLC and comparison 
of T4 concentrations in T4AA positive serum samples 
obtained by CIA and HPLC
The T4 concentrations measured using both CIA and HPLC 
were comparable, irrespective of the presence or absence of 
T4AA (Table 3). In serum samples with low T4 concentrations 
obtained by CIA, no peak was detected in the HPLC analysis, 
which was equivalent to a concentration below 0.5 μg/dL.
Discussion
The measurement of T4 and TSH is widely used in diagnosing 
primary hypothyroidism in dogs. However, these serum 
concentrations can be altered by non-thyroidal illness or as 
a side effect of certain drugs, leading to confusing results and 
a more difficult diagnosis, even if clinical signs suggestive 
of hypothyroidism are present [8]. THAA have been suspected 
of interfering with immunological hormone assays, leading 
to falsely elevated T4 concentration and thereby inappropriately 
ruling out hypothyroidism [5,14]. TgAA have been detected 
in approximately 50% of dogs with a AIT [1,11], and have 
been reported to be associated with autoantibodies directed 
against T4 and T3 [9].
In the present study, T3AA and T4AA were detected in 
3.8% and 0.5%, respectively, of samples from dogs with 
clinical signs suggestive of hypothyroidism. These figures 
are comparable to those of Nachreiner et al. [14], who reported 
that 4.6% and 0.6% of dogs with suspected hypothyroidism 
were positive for T3AA and T4AA, respectively. Accordingly, 
T4AA seem to be rarer compared to T3AA in our study, 
which is in general agreement with other published data 
[9,14,16,20,22]. In contrast to the findings of Nachreiner et 
al. [14] who detected significantly more THAA in females 
than males, there was no evidence of gender influencing the 
prevalence of THAA in the present study. This may be due 
to different selection criteria and the smaller sample size 
analyzed in the present study. Significantly more dogs from 
Group 1 (clinical signs of hypothyroidism, low T4, elevated 
TSH) were positive for THAA compared to clinically 
suspicious dogs with questionable hormone concentrations 
(Group 2 and 3) or hormone concentrations within the 
laboratory reference range (Group 4).
However, the incidence of THAA in dogs with different 
onset of AIT and different severity of clinical signs were 
difficult to compare because in the final stage of thyroid 
destruction production of autoantibodies ceases. The 
presence of THAA in Group 2∼4 could be interpreted as 
early signs of AIT. This finding is in agreement with Graham 
et al. [11] who suggested that TgAA can be measured in dogs 
developing hypothyroidism caused by AIT but still have 
enough functional thyroid tissue to provide normal or only 
slightly decreased T4 concentrations without increased 
TSH. These dogs may already have early clinical signs 
consistent with hypothyroidism like lethargy, increased 
body weight and poor hair coat even with only slightly 
lowered or normal T4 concentrations.
In humans with AIT, a slightly increased risk for developing 
T4AA under substitution therapy with T4 has been suggested 
[3], but in the present study none of the already substituted 
dogs were positive for T4AA. Similar to other data in the 
literature about TgAA [16], the percentage of T3AA binding 
of one dog in our study was reduced during a 9 month follow- 
up.
In contrast to previous findings about the occurrence of 
TgAA in clinically healthy dogs [7], in the present study no 
clinically healthy dog was positive for THAA.
THAA determinations are recommended when clinical 
signs do not match with laboratory results [13]. However, Autoantibodies against thyroid hormones in dogs    195
the possible interference of THAA with different immunological 
and non-immunological hormone measurement methods 
has not been properly elucidated in dogs. Four of five 
T4AA positive dogs of the present study had low T4 
concentrations as measured by CIA. No dog with clinical 
signs due to hypothyroidism and normal T4 but elevated 
TSH concentrations was positive for T4AA (Group 2). 
This result may undermine the hypothesis that T4AA 
interferences can potentially lead to falsely elevated T4 
concentration and confuse the diagnosis of hypothyroidism.
In humans, T4 determination using HPLC is an established 
reference method for validating assays and the technique 
has been widely applied to the measurement of iodothyronines 
[4,10]. The T4 concentrations of T4AA positive samples as 
analysed by HPLC revealed good agreement with the 
immunological T4 assay results irrespective of T4AA titer. 
This result may indicate that the CIA is less sensitive to 
T4AA interference. This is the first time that T4AA positive 
serum samples have been assayed for T4 using HPLC and 
an immunoassay. However, the magnitude of the results 
was not enough to make a universally valid prediction 
about T4AA interferences in chemiluminescence assays. 
However, interference seems unlikely. No dog suggestive 
for subclinical thyroiditis (normal T4, elevated TSH) was 
positive for T4AA. Moreover the T4 concentration in T4AA 
positive samples obtained by HPLC and immunoassay 
showed a good correlation. In a previous study a direct 
linear correlation was observed between T3AA and apparent 
serum T3 concentrations as measured by RIA, indicating a 
possible interference of the autoantibodies with the RIA 
[9]. If the radioactive tracer (T3 labelled with 
125I) binds to 
the autoantibodies in serum as well as to the assay antibodies 
a falsely increased value may occur, depending on the 
affinity of the assay and autoantibodies respectively. In a 
solid phase RIA, paradoxically low T4 was measured [12]. 
Theoretically, the CIA used in this study should also have 
shown falsely elevated T4 concentrations; however, not 
every assay for T4 will be influenced in the same way 
because antibodies with different affinities and binding 
characteristics as well as different separation methods are 
employed by manufacturers. Presumably, immunoassay 
with monoclonal antibodies is less sensitive to interference 
by autoantibodies than the RIA system with polyclonal 
antibodies [14]. However, it should be noted that Nachreiner 
et al. [14] found that only 17 of 1,000 T4AA positive samples 
from hypothyroid dogs were likely to be falsely elevated. 
Ferguson et al. [8] concluded that antibodies only interfere 
with the immunoassay if high autoantibody titers are 
reached. In the present study, one sample had a high T4AA 
titer (＞50%) but T4 concentrations obtained by CIA and 
HPLC were comparable. This reveals that a respective bias 
is most unlikely. Furthermore, varying affinities of the 
detected autoantibodies have been described in humans, 
which could explain different influences in assay systems 
[2,6,12,15].
Further studies with T4AA positive serum samples are 
needed to confirm these data, particularly in view of the 
reported differences in autoantibody affinities.
In conclusion this study was the first survey in Germany 
on the prevalence of thyroid hormone autoantibodies in 
treated (levothyroxine) and non-treated hypothyroid dogs 
and dogs suspected to be hypothyroid, and the results were 
comparable to published data. When applying HPLC analysis 
to T4AA positive serum samples, no falsely elevated T4 
values as measured by CIA could be verified. Furthermore, 
no T4AA was detected in the group of dogs with normal T4 
and elevated TSH, indicating that the expected interference 
of T4AA did not feature in the present study. The data from 
the present study suggest that, when using a comparable 
chemiluminescence immunoassay, analysis of T4AA does 
not provide more information than TGAA for the diagnosis 
of hypothyroidism in dogs.
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